FDA overrides adcomm, shoots down KemPharm’s opioid

FDA

A little more than a month ago a large majority of members of an FDA advisory committee had no problem waving through a new opioid pain drug from KemPharm. But today the biotech says that the agency has decided to slam the door shut on a marketing approval for Apadaz--at least for now.

KemPharm ($KMPH) had started out with high hopes of getting the panel and the agency to agree to label the drug as abuse deterrent, arguing that an opioid that could only be activated by enzymes in the intestinal tract would be difficult to get high off of by snorting, injecting or smoking it. The outside experts signed off on its analgesic effect, but were left unimpressed by the data provided on abuse deterrence.

By 16 to 4, the panelists concluded that the opioid Apadaz, a prodrug of hydrocodone and benzoic acid combined with acetaminophen, should get a green light. But by 18 to 2 they shot down a question added at the 11th hour, concluding that the drug should not be labeled as abuse deterrent.

Virtual Event

Virtual Clinical Trials Online

This virtual event will bring together industry experts to discuss the increasing pace of pharmaceutical innovation, the need to maintain data quality and integrity as new technologies are implemented and understand regulatory challenges to ensure compliance.

Evidently the FDA insiders were even less impressed, issuing its complete response letter. The company gave no hint about what the FDA will require them to do to get the CRL reversed and the pain drug on the market.

The rejection comes at a time that the opioid epidemic has become a central issue in communities across the country. Today a new study from Johns Hopkins noted that more than half of the people taking an opioid end up setting some aside to share or use later. And that is contributing to an epidemic that has roiled the nation and put all opioids under an intense spotlight. In many ways, this is a bad time to try to introduce a rival that can't be considered abuse deterrent.

“We are currently evaluating the points raised in the CRL and intend to request an End of Review meeting with the Agency to determine the pathway forward for Apadaz,” noted KemPharm CEO Travis Mickle in a prepared statement.

- here's the release

Related Articles:
Pfizer opioid given mixed report after posing a ‘quandary’ for FDA panel
FDA panel recommends approval of Teva’s abuse-deterring opioid, despite reservations
In a comeback win, FDA OKs Titan’s implanted drug for opioid addicts
FDA advisers spurn KemPharm’s abuse-deterrent claim for opioid

Read more on

Suggested Articles

Oncoceutics’ chairman and CEO Wolfgang Oster has abruptly left the biotech, leaving COO Lee Schalop, M.D., as its new leader.

Naseem Amin, formerly of Biogen, is stepping up to the executive chairman position to lead the biotech investor through a potentially tricky period.

The trial builds on in vitro evidence that the adenosine nucleoside analog is effective against pathogens including the MERS and SARS coronaviruses.